PCM
BSX icon

Parsifal Capital Management’s Boston Scientific BSX Stock Holding History

Parsifal Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-631,000
Closed -$22.2M – 16
2020
Q2 		$22.2M Buy
631,000
+270,500
+75% +$9.74M 6.56% 6
2020
Q1 		$11.8M Buy
+360,500
New +$14.1M 4.31% 10

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parsifal Capital Management's BSX Position: Q3 2020 in Review

Parsifal Capital Management sold out of Boston Scientific (BSX) in Q3 2020, closing a stake of 631,000 shares — an estimated $22.2M sold.

Parsifal Capital Management first reported a position in BSX in Q1 2020 and held it in 2 quarters. The position peaked at $22.2M in Q2 2020. 843 funds tracked by Wall St. Rank hold BSX as of Q3 2020.

  • Parsifal Capital Management reported no remaining Boston Scientific position as of Q3 2020 after selling out during the quarter.
  • Parsifal Capital Management sold 631,000 Boston Scientific shares in Q3 2020, an estimated $22.2M.
  • Parsifal Capital Management first reported a position in Boston Scientific in Q1 2020 and held it in 2 quarters.
  • Parsifal Capital Management's Boston Scientific position peaked at $22.2M in Q2 2020.
  • 843 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2020.

Based on Parsifal Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.